NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Thanks, BB,

AE put an article by Michale Lim current a faculty at Stanford in which tumor associated antigens (TAA) were mentioned. He said since the antigen are present in both tumor and normal cells, the robustness of the vaccines using TAAs may be limited. We know that the combination of DCVax-L and poly-iclc has no such issue. Likewise the currently undergoing combo trial, which from one perspective shows how extraordinary DCVax-L is.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521200/

Glioma-associated antigens (GAA) are genetic mutations that are present in both tumor and
normal cells but are preferentially expressed at a higher level in the tumor cells. Many GAAs have
been studied over the years such as gp100, EphA2, IL-13Ra2, and survivin. However, GAAs may limit
the ability of the immune system to generate a robust response given their co-expression on normal
tissue and subsequent host immunotolerance.